Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening

SMYD3 (SET and MYND domain-containing protein 3) is a protein lysine methyltransferase that was initially described as an H3K4 methyltransferase involved in transcriptional regulation. SMYD3 has been reported to methylate and regulate several nonhistone proteins relevant to cancer, including mitogen-activated protein kinase kinase kinase 2 (MAP3K2), vascular endothelial growth factor receptor 1 (VEGFR1), and the human epidermal growth factor receptor 2 (HER2). In addition, overexpression of SMYD3 has been linked to poor prognosis in certain cancers, suggesting SMYD3 as a potential oncogene and attractive cancer drug target. Here we report the discovery of a novel SMYD3 inhibitor. We performed a thermal shift assay (TSA)-based high-throughput screening (HTS) with 410,000 compounds and identified a novel benzodiazepine-based SMYD3 inhibitor series. Crystal structures revealed that this series binds to the substrate binding site and occupies the hydrophobic lysine binding pocket via an unprecedented hydrogen bonding pattern. Biochemical assays showed substrate competitive behavior. Following optimization and extensive biophysical validation with surface plasmon resonance (SPR) analysis and isothermal titration calorimetry (ITC), we identified BAY-6035, which shows nanomolar potency and selectivity against kinases and other PKMTs. Furthermore, BAY-6035 specifically inhibits methylation of MAP3K2 by SMYD3 in a cellular mechanistic assay with an IC50 <100 nM. Moreover, we describe a congeneric negative control to BAY-6035. In summary, BAY-6035 is a novel selective and potent SMYD3 inhibitor probe that will foster the exploration of the biological role of SMYD3 in diseased and nondiseased tissues.

[1]  Rong Li,et al.  Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3. , 2019, ACS medicinal chemistry letters.

[2]  M. Bartolini,et al.  Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends. , 2019, Future medicinal chemistry.

[3]  Clara D. Christ,et al.  Abstract 1646: Discovery and characterization of BAY-6035, a novel benzodiazepine-based SMYD3 inhibitor , 2018, Cancer Chemistry.

[4]  Jodi Gureasko,et al.  Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation , 2018, PloS one.

[5]  T. Lu,et al.  Direct and Enantioselective Synthesis of N-H-Free 1,5-Benzodiazepin-2-ones by an N-Heterocyclic Carbene Catalyzed [3+4] Annulation Reaction. , 2018, Chemistry.

[6]  Jennifer A. Ward,et al.  A chemical biology toolbox to study protein methyltransferases and epigenetic signaling , 2018, bioRxiv.

[7]  Hao Zhou,et al.  Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells. , 2017, Oncology letters.

[8]  Yusuke Nakamura,et al.  Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization , 2017, Cancer medicine.

[9]  M. Rueping,et al.  Asymmetric Hydrogenation of Cyclic Imines and Enamines: Access to 1,5-Benzodiazepine Pharmacophores , 2016, Synthesis.

[10]  Yusuke Nakamura,et al.  SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1 , 2016, Oncotarget.

[11]  A. Fersht,et al.  Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs , 2016, ACS chemical biology.

[12]  E. Li,et al.  SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. , 2016, Human pathology.

[13]  Tony W Dean,et al.  Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. , 2016, Structure.

[14]  Clara D. Christ,et al.  Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2 , 2016, Journal of medicinal chemistry.

[15]  P. Moulos,et al.  Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development. , 2016, Cancer cell.

[16]  J. Min,et al.  Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase* , 2016, The Journal of Biological Chemistry.

[17]  Tim J. Wigle,et al.  Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. , 2016, ACS medicinal chemistry letters.

[18]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[19]  Haley O. Tucker,et al.  C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis , 2015, Oncotarget.

[20]  H. Liang,et al.  Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer , 2015, Tumor Biology.

[21]  Joshua Holcomb,et al.  Structure and Function of SET and MYND Domain-Containing Proteins , 2015, International journal of molecular sciences.

[22]  R. DePinho,et al.  Cancer signaling: when phosphorylation meets methylation , 2014, Cell Research.

[23]  A. Butte,et al.  SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer , 2014, Nature.

[24]  Hao Zhou,et al.  Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells. , 2014, Cancer letters.

[25]  C. Liu,et al.  SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription. , 2013, Journal of the National Cancer Institute.

[26]  Mark E Bunnage,et al.  Target validation using chemical probes. , 2013, Nature chemical biology.

[27]  Quanbo Zhou,et al.  Epigenetic regulation of miR‐124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3 , 2012, FEBS letters.

[28]  D. Xie,et al.  High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. , 2012, Human pathology.

[29]  B. Garcia,et al.  Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation , 2012, Epigenetics.

[30]  J. Weitzman,et al.  SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. , 2012, Cancer research.

[31]  Wolfgang Rottbauer,et al.  Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization. , 2012, Genes & development.

[32]  H. Ikeuchi,et al.  Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. , 2011, European journal of cancer.

[33]  T. Beißbarth,et al.  Mutated KRAS results in overexpression of DUSP4, a MAP‐kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas , 2010, Genes, chromosomes & cancer.

[34]  Tao Xi,et al.  Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. , 2009, Cancer letters.

[35]  Q. Wei,et al.  Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking , 2008, Cancer science.

[36]  Guobin Wang,et al.  Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. , 2007, World journal of gastroenterology.

[37]  Yusuke Nakamura,et al.  The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. , 2007, Cancer research.

[38]  S. Kyo,et al.  The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. , 2007, Cancer research.

[39]  Yusuke Nakamura,et al.  Enhanced SMYD3 expression is essential for the growth of breast cancer cells , 2006, Cancer science.

[40]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[41]  Yusuke Nakamura,et al.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells , 2004, Nature Cell Biology.

[42]  T. Nagao,et al.  Reactions of 3-phenylglycidic esters. V: Reaction of methyl 3-(4-methoxyphenyl)glycidate with 2-nitroaniline and synthesis of 1,5-benzodiazepine derivatives , 1985 .

[43]  W. Ried,et al.  Über heterocyclische Siebenringsysteme, I. Mitteil.: Das 7‐Methyl‐2.3‐benzo‐1.4‐diaza‐cyclohepten‐(2)‐on‐(5) und seine Derivate , 1953 .

[44]  Vincent Mariaule,et al.  Estimation of crystallization likelihood through a fluorimetric thermal stability assay. , 2014, Methods in molecular biology.

[45]  H. Liang,et al.  Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer , 2014, Medical Oncology.

[46]  Joseph D. Kwasnoski,et al.  High-density miniaturized thermal shift assays as a general strategy for drug discovery. , 2001, Journal of biomolecular screening.